---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-098539"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2023-04-12T23:59:59+00:00"
generated_at: "2026-06-17T03:07:07.475078+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Aeglea cuts 83% of workforce, explores strategic alternatives after mixed trial data

## Summary
- Workforce reduced by 50 (~83% of headcount) to ~10 employees; $6.2M restructuring charges expected in Q2 2023.
- CBO Michael Hanley and CMO Linda Neuman depart effective April 14, 2023.
- Interim Phase 1/2 pegtarviliase trial: dose-dependent homocysteine reduction in cohorts 1–2 but not consistent in cohort 3; ADAs observed.
- Company engages Wedbush Securities to explore strategic alternatives including sale or merger; no timetable set.
- Pegzilarginase MAA under EMA review with potential EU decision in late 2023; partnered with Immedica.

## SEC filing metadata
- accession: 0001193125-23-098539
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2023-04-12T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.05, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000119312523098539/0001193125-23-098539-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000119312523098539/d485603d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-098539
- JSON: https://secwatch.observer/filing/0001193125-23-098539.json
- Plain text: https://secwatch.observer/filing/0001193125-23-098539.txt

## Key facts
- Executive change
  Linda Neuman departed as Chief Medical Officer at Spyre Therapeutics, Inc..
  - Action: departing
  - Role: Chief Medical Officer
  source text: Michael Hanley, the Company’s Chief Business Officer, and Linda Neuman, the Company’s Chief Medical Officer, will be departing from the Company, effective April 14, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000119312523098539/0001193125-23-098539-index.htm
- Executive change
  Michael Hanley departed as Chief Business Officer at Spyre Therapeutics, Inc..
  - Action: departing
  - Role: Chief Business Officer
  source text: Michael Hanley, the Company’s Chief Business Officer, and Linda Neuman, the Company’s Chief Medical Officer, will be departing from the Company, effective April 14, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000119312523098539/0001193125-23-098539-index.htm
- Restructurings & Charges
  Spyre Therapeutics, Inc. announced a restructuring with charges of approximately $6.2 million (50 people, or approximately 83% of the Company’s existing headcount).
  - Type: restructuring
  - Charge: approximately $6.2 million
  - Headcount: 50 people, or approximately 83% of the Company’s existing headcount
  source text: headcount, retaining approximately 10 employees. The restructuring was communicated to employees on April 11, 2023. The Company estimates that it will incur approximately $6.2 million in employee-related restructuring charges in connection with the restructuring, consisting of (i) approximately $5.6 million in cash-based expenses related to employee severance
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000119312523098539/0001193125-23-098539-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.